• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Qualaquin (quinine sulfate) Capsules, USP

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- November 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


 

Summary View

 

Sections Modified

PRECAUTIONS

  • Drug Interactions
    • Effects of Drugs and Other Substances on Quinine Pharmacokinetics
      • Drugs and other substances that alter the absorption, distribution, metabolism, and excretion of quinine may increase or decrease quinine concentrations (see CLINICAL PHARMACOLOGY).
      • Cigarette Smoking (CYP1A2 Inducer)
      • Cimetidine, ranitidine (nonspecific CYP450 inhibitors)
    • Effect of Quinine on the Pharmacokinetics of Other Drugs
      • Atorvastatin (CYP3A4 substrate)